Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC
  • USA - English


News provided by

Wright & Schulte LLC

Dec 20, 2014, 03:00 ET

Share this article

Share toX

Share this article

Share toX

Xarelto Lawsuits Consolidated In Louisiana MDL
Xarelto Lawsuits Consolidated In Louisiana MDL
Youtube
Youtube

If you believe you have suffered internal bleeding due to Xarelto contact the attorneys at Wright & Schulte LLC For a Free legal consult buy calling 1-800-399-0795 or visit www.yourlegalhelp.com

Post this

Columbus, OH (PRWEB) December 20, 2014 -- Xarelto bleeding lawsuits filed by men and women contend they suffered uncontrollable bleeding and other serious side effects will be consolidated in the U.S. District Court, Eastern District of Louisiana for coordinated pretrial proceedings, Wright & Schulte LLC reports. The U.S. Judicial Panel on Multidistrict Litigation (JPML) issued an order Friday to transfer 21 Xarelto lawsuits and over 30 potential tag-along actions pending in 22 federal courts to the Louisiana district court for coordination by Judge Eldon E. Fallon. The request by plaintiffs in pending Xarelto complaints to establish a multidistrict litigation (MDL) was granted after the panel found that the Xarelto bleeding lawsuits share common questions of fact regarding the development, manufacturing and marketing of the blood thinner. The panel wrote the Xarelto complaints also had common allegations including Bayer AG, the Germany-based manufacturer of Xarelto, and Johnson & Johnson’s subsidiary, Janssen Pharmaceuticals Inc., which markets Xarelto, did not adequately warn doctors, patients and consumers about the severe or fatal bleeding risks associated with the blood thinner and there is no reversal agent available to counteract Xarelto’s anticoagulation effects. The JPML’s order also stated that centralizing the cases will prevent inconsistent potential rulings and eliminate duplicative discovery. (In re: Xarelto (Rivaroxaban) Products Liability Litigation, MDL 2592).

The firm continues to offer free legal consultations to men and women across the country who believe they have suffered serious side-effect after uncontrolled bleed from the blood thinner Xarelto. To speak with one of the firms attorneys contact Wright & Schulte LLC by calling 1-800-399-0795 or visit http://www.yourlegalhelp.com and submit a request form.

Bayer and Janssen objected to a Xarelto MDL consolidation and asked the JPML to allow an informal coordination of the cases between the parties. The panel wrote in its order that informal coordination among plaintiffs and the defendants is unlikely because there are more than two dozen plaintiffs’ law firms and discovery located in a foreign country. Since the defendants were not opposed to Louisiana being an alternative court, the JPML selected Louisiana because it would provide a “geographically central forum for this nationwide litigation.” The panel’s order further said that Judge Fallon is “well-versed in multidistrict litigation” and the panel is “confident that he will steer this matter on a prudent course.” (In re: Xarelto (Rivaroxaban) Products Liability Litigation, MDL 2592).

Xarelto is an oral anticoagulant first approved by the U.S. Food and Drug Administration (FDA) in 2011. Xarelto is used to treat blood clots in the leg (deep vein thrombosis) and lungs (pulmonary embolism) and to reduce the risk of stroke and blood clots in patients with atrial fibrillation (irregular heart rhythms). Xarelto and Pradaxa are considered new generation blood thinners because prior to their approval, the FDA had only approved one blood thinner 60 years ago and that was warfarin (Coumadin, Jantoven). However, unlike warfarin which has vitamin K as a reversal agent for bleeding, Xarelto does not have an antidote should severe bleeding occur in patients using the blood thinner, according to the FDA. [fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm326654.htm, November 2, 2012] [fda.gov/Drugs/NewsEvents/ucm405148.htm, July 17, 2014]

The increased use of Xarelto has resulted in more serious adverse events reported to the FDA, according to the Institute for Safe Medicine Practices (ISMP). In May, the ISMP stated in its QuarterWatch Report, which monitors and analyzes serious adverse drug events reported to FDA, that there were 680 serious adverse events associated with Xarelto (rivaroxaban) compared to 528 for Pradaxa (dabigatran) in the first quarter of 2013. The ISMP noted that this was the first time Xarelto complications had outnumbered those involving Pradaxa. The ISMP also reported that outpatient prescriptions for Xarelto increased to nearly 1 million prescriptions per quarter while Pradaxa has steadily declined since peaking in early 2012. The ISMP suggested that this trend is due to doctors changing prescriptions from Pradaxa to Xarelto.
[ismp.org/quarterwatch/pdfs/2013Q1.pdf, May 7, 2014]

Court documents indicate that among the plaintiffs who filed the MDL consolidation request to the JPML was an Illinois woman who alleges that after she began taking the blood thinner medication in November 2013, she experienced uterine bleeding a few weeks later. The lawsuit alleges that the life-threatening episode caused the woman to be hospitalized and she had to receive multiple transfusions. The Xarelto bleeding side-effects complaint against Bayer and Janssen purports that the companies failed to adequately warn doctors and their patients about the bleeding risks associated with using Xarelto.The lawsuit was filed in the U.S. District Court, Southern District of Illinois. (3:14-00987)

About Wright & Schulte LLC
Wright & Schulte LLC, an experienced personal injury firm, is dedicated to the belief that America’s legal system should work for the people. Every day, the attorneys of Wright & Schulte LLC stand up for the rights of people who have been injured or wronged and fight tirelessly to ensure that even the world’s most powerful corporations take responsibility for their actions. If you’re looking for a law firm that will guarantee the aggressive and personal representation you deserve, please do not hesitate to contact Wright & Schulte LLC today. Free Xarelto bleeding lawsuit case evaluations are available through yourlegalhelp.com or by calling 1-800-399-0795.

Contact:
Wright & Schulte LLC
812 East National Road
Vandalia, Ohio 45377
1-800-399-0795
http://www.yourlegalhelp.com
Like us on Facebook
Follow us on Twitter
Join us on Google+

Richard Schulte, Wright & Schulte LLC, http://yourlegalhelp.com/, +1 1-800-399-0795, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.